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Summary Glucose and lipid metabolism in the brain, liver and in a transplanted tumour were found to be
variously altered within 2 to 3 h of administering single doses of the radiosensitizer Ro-03-8799 to normal and
tumour-bearing mice. Hepatic lactate and glycerol-3-phosphate (G3P) levels were decreased but those of the
ketone body ,B-hydroxybutyrate (,B-HOBu) were raised. However, in the tumour, these levels were all
enhanced. The lactate levels in brain remained relatively constant but both fl-HOBu and G3P levels were
altered in a manner similar to that in the liver. The levels of glucose were approximately doubled in blood,
brain and tumour, but whereas tumour G6P levels increased, those in the brain were lowered to below the
limits of detection. Hepatic glucose levels were significantly decreased after 1 h but G6P levels were not
affected. These changes could neither be related to inhibitory effects on hepatic glucokinase or brain
hexokinase activity nor to limiting amounts of ATP in both tissues. However, the activity of glucose-6-
phosphatase (G6P'ase) was distinctly raised in the liver and the hepatic glycogen stores were also rapidly
lowered. Overall, the results suggest that Ro-03-8799 exerts a stimulatory effect on glucose production in the
liver. In both liver and brain the levels of free fatty acids and phospholipids were increased whereas those of
esterified fatty acids were lowered. Most importantly, the changes in metabolite levels affect the cellular redox
couples; those of the cytosol (lactate/pyruvate; G3P/dihydroxyacetone phosphate (DAP)) are directed towards
the oxidised state in the liver but to a more reduced state in the tumour. The mitochondrial couple (/3-
HOBu/acetoacetate (AcAc)) in both tissues is shifted towards the reduced state. These metabolic changes may
result in an increase in the degree of hypoxia in the tumour and may well play an important role in the
development of neuropathies.
The current interest in the oncological use of nitroimidazole
electron-affinic compounds is based upon their preferential
radiosensitizing and cytotoxic effects on hypoxic cells
(Adams, 1981) as well as their ability to chemosensitize
several anti-tumour cytotoxic drugs (Siemann, 1982; Millar,
1982). In particular, misonidazole (MISO) has been subjected
to extensive clinical trials as a radiosensitizer but its efficacy
has been severely limited because of its peripheral neuro-
toxicity in patients (Dische, 1984).
Workman (1980) has shown that the lipophilicity of
sensitizers may be an important factor in their pharmaco-
kinetic and toxic behaviour in vivo. Thus, less lipophilic
analogues of MISO e.g. desmethylmisonidazole (DEMISO)
and SR-2508 were progressively excluded from both the
central and peripheral nervous system but not from tumours
in laboratory animals. In spite of this, however, clinical
studies with DEMISO (Dische et al., 1981) have shown
an extensive occurrence of neuropathies in patients, similar
to that seen with MISO.
At present, the sensitizers SR-2508 and Ro-03-8799 are
undergoing clinical tests (Coleman, 1985; Roberts et al.,
1986), and although both compounds appear to be more
superior than MISO by a factor of about 5 to 8 from in vitro
and in vivo data in terms of overall net gain (Fowler, 1985),
it is already apparent that dose administration of Ro-03-8799
will be limited by central neurotoxicity (Roberts et al., 1986).
Although sensitizers are metabolically active both in vitro
and in vivo (Varghese & Whitmore, 1984; Chin & Rauth,
1981; Heimbrook & Sartorelli, 1986), very little is known
biochemically about their action as a radiosensitizing,
chemosensitizing or neurotoxic agent in vivo. Treatment of
mice with MISO has led to changes in metabolite levels
which have resulted in marked alterations to the cellular
redox systems in normal tissues and transplanted tumour
(Tamulevicius et al., 1984a). From previous studies on mice
it was shown that nerve fibres undergo extensive demye-
lination after multiple daily doses of MISO (Adams et al.,
1978), and if this is directly related to neurotoxicity, we have
investigated the possibility of whether this latter effect may
be linked to disturbances in lipid metabolism in vivo, particu-
larly as MISO has been found to lower the levels of G3P, a
precursor of phospholipids (Tamulevicius et al., 1984a) and
inhibit fatty acid synthesis (Jones et al., 1981). Here, we
report the effects of single dose treatments with Ro-03-8799
on glucose and lipid metabolism for periods of up to 24h in
the liver, the brain and a transplanted adenocarcinoma of
tumour - and non-tumour bearing mice.
Materials and methods
Animals
The animals used were 8-12 week old adult male mice
(strains: Radiologisches Institut 'Heiligenberger', Freiburg
i.Br., FRG, and C57 Bl 6J mice, colony bred in our
institute). They were fed on a standard diet (Altromin) and
given acidified water, pH 3, ad libitum.
Tumour system
An adenocarcinoma, E-0771, obtained from the Institut fur
Medizin, Kernforschungsanlage Jiilich, FRG, was main-
tained by serial transplantation in C57 mice. Animals
received i.m. injections of tumour cell suspension (175 x 103
viable cells in 0.3ml physiological saline) in their hind legs.
Viability was determined by erythrosin staining. For experi-
mental purposes, tumours were allowed to grow for 7 days,
reaching a diameter of -9mm and volume of 0.38cm3.
The volume was determined from the formula V=(d/2)3x
4.19.
Sensitizer
The sensitizer Ro-03-8799 (2-nitro-ac-(piperidinomethyl)-
1-imidazole ethanol, was kindly supplied by Dr C. Smithen,
Roche Products, Welwyn, UK and Dr S. de Garis,
Hoffmann-La Roche, Basle, Switzerland. Ro-03-8799 was
dissolved in physiological saline (25mgml-1) and all animals
received i.p. doses of 1 gkg- 1 (- 4mM) body weight.
Control animals were given saline alone.
Blood samples
Blood was collected from the orbital vein of tumour-bearing
animals into glass tubes coated with sodium citrate. Plasma
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was obtained by centrifugation at 2,000g for 10min and
stored at -20°C.
HPLC
The levels of Ro-03-8799 in plasma, brain and tumour from
C57 mice were determined by HPLC after extraction with
methanol (1:10; w/v) as described by Stratford et al. (1982),
expect that the eluents were monitored at 335 nm.
Metabolite determination
At various times after treatment of mice with Ro-03-8799 or
saline tumour, brain and liver tissues were rapidly removed
under light ether anaesthesia, the latter with precooled
stainless steel tongs immersed in liquid nitrogen and
homogenised in 4% perchloric acid. After centrifugation at
10,000g for 10min, the supernatants were neutralised with
5M K2CO3 and the following metabolites determined by
standard enzymatic methods (see Bergmeyer, 1970 for
references); Glucose and glucose-6-phosphate (G6P)
(Bergmeyer et al.), fructose-1,6-bisphosphate (FDP) and
dihydroxyacetone phosphate (DAP) (Bucher & Hohorst),
glycerol-3-phosphate (G3P) (Hohorst), pyruvate (P) (Czok &
Lamprecht), lactate (L) (Noll), acetoacetate (AcAc)
(Mellanby & Williamson), P-hydroxybutyrate (fl-HOBu)
(Williamson & Mellanby) and ATP (Jaworek et al.)
Lipids (free fatty acids, esterified fatty acids and phospho-
lipids) were determined as described by Tamulevicius et al.
(1984b).
Measurement ofenzyme activities
The enzyme activities of hexokinase in brain and glucokinase
in liver were assayed at 25°C by the method of Crisp &
Pogson (1972), in the presence of 0.5mM and 200mM
glucose respectively. Glucose-6-phosphatase in both tissues
was determined as described by Baginski et al. in Bergmeyer
(1970). All enzyme activities are expressed as U-'g tissue
wet wt. One unit of enzyme is the activity which produces
1 timol of measured product min-I under the conditions of
the assay.
Glycogen and bloodglucose determination
Blood glucose was determined according to the procedure of
Bergmeyer et al. in Bergmeyer (1970) and hepatic glycogen
levels were measured spectrophotometrically with anthrone
reagent as described by Schubert (1981).
Body temperature measurement
Body temperatures of animals were measured rectally with a
digital thermometer (Ellab, Type du 3 S, Copenhagen) using
ARM 4 thermister probes.
Results
Pharmacokinetics ofRo-03-8799 in C57 mice
The distribution of the sensitizer in blood plasma, brain and
tumour from C57 mice is shown in Figure 1. Peak plasma
levels of about 330 ugml-1 were obtained within 15min after
drug administration whereas the uptake of Ro-03-8799 into
the tumour was slower than into the brain, both tissues
reaching peak levels of 200 and 250 ggg-1 at 30 and 15min
respectively. Plasma levels then decreased continuously with
an apparent half-life of about 45min over a 3 h period but
the levels of Ro-03-8799 in both brain and tumour remained
plateaued for up to 60min and exceeding those of the
plasma. Over the next 2h, the decrease seen in tumour levels
closely paralleled the decrease in the plasma levels, with an
apparent half-life of 35 min, whilst brain levels were still
high at 120min as indicated by a brain/plasma ratio of -3
at this time.
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Figure 1 Concentration of Ro-03-8799 in
tumour of C57 Bl mice after treatment with
i.p. Mean +s.e. (n=6-8 animals).
brain, plasma and
1 gkg-1 Ro-03-8799
Studies with normal mice
Effects of Ro-03-8799 on glucose metabolism The adminis-
tration of Ro-03-8799 to normal mice was found to cause
the most profound changes in glucose metabolism in the
liver and brain within 2 to 3h. However, saline alone did not
significantly affect the metabolite levels at the various time
points studied, and are indicated here as 0h values. As
shown in Figure 2, the lactate levels in these tissues were
variously affected. Thus the hepatic levels were markedly
lowered by -40% after 2h but returned to normal levels
thereafter, whereas those in the brain remained relatively
unaffected over the 24h period. Although the levels of
pyruvate in both tissues remained fairly constant throughout,
sensitizer treatment resulted in a lowering of the
lactate/pyruvate ratio in the liver by - 15% over the first
2h. Similarly, the levels of glucose and its phosphate ester,
G6P, were differently altered in both brain and liver. Brain
glucose levels were increased approximately 2-fold while
those of G6P were decreased by about the same extent at
this time. The levels of G6P in brain, however, remained
continuously decreased to below the limits of detection up to
24h whereas those of glucose returned to normal. In
contrast, hepatic glucose levels were initially decreased after
1 h followed by a marked increase one hour later but G6P
levels were not greatly affected over the period of obser-
vation. Of the other glycolytic intermediates investigated,
FDP and DAP levels were not markedly altered in the liver
whereas the level of FDP in brain was only significantly
decreased (-2-fold) after I h. However, in both tissues at
this time the levels of G3P were significantly lowered by
- 80% (liver) and 40% (brain) of their respective controls.
Whereas these returned to normal in brain, hepatic levels
remained lowered by 40% over the initial three hour
period. As a result of these early metabolic changes both the
hepatic and brain G3P/DAP ratios were decreased.
Effects on blood glucose levels and hepatic glycogen content
As shown in Table I, blood glucose levels in normal mice are
significantly enhanced over the initial 2h period but reached
basal levels 4h after sensitizer treatment. At the same time,
the glycogen levels are rapidly lowered but which also returned
to normal values after 4h.
Effects on ketone body production In comparison to the
effects on the end products of glycolysis, i.e. pyruvate and
lactate, the levels of AcAc and fl-HOBu were affected
differently by the sensitizer (Figure 2). Hepatic AcAc levels
were only significantly enhanced at later times (12 to 24h)
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Table I Effect of Ro-03-8799 (lgkg-', i.p.) on
hepatic glycogen and blood glucose levels in
normal mice, up to 4h after administration
Time Glycogen Glucose
(h) (mgg 1) (jmolmi-1)
0 14.2+1.3 8.66+0.27
l 8.9+ .la 13.69+0.58a
2 10.8+0.4a 16.17+1.21a
4 18.7+ 1.2 8.13+0.42
ap<0.01, Student's t-test, with respect to
control group.
Values aregiven as mean + s.e. of6-12 animals.
whereas the corresponding levels of fl-HOBu were raised by
a factor of -2.5 over the first 3 h. In consequence, the /1-
HOBu/AcAc ratio was initially found to be approximately
doubled, but reduced by the same extent at the later times.
In brain, AcAc levels remained relatively unaltered through-
out and those of fl-HOBu were only raised about 2-fold after
2h.
Effects of Ro-03-8799 on lipid metabolism The levels of the
free fatty acids and phospholipid fractions in the liver and
brain were significantly enhanced 1 h after administration of
Ro-03-8799 (Figure 3). Whereas the amounts of both
fractions in the brain then decreased sharply to approxi-
mately those of the controls after 2h and remained at
around these levels for up to 12h, the corresponding hepatic
fractions, however, remained plateaued over the initial 3h
period. In contrast, no significant changes in the levels of the
esterified fatty acid fraction in either the brain or liver were
seen after 1 h but both decreased markedly to below control
levels over the 3 h period and remained lowered for up to
12 h.
Effects of sensitizer on enzyme activities and ATP levels
Determinations of the enzyme activities involved in the inter-
conversion of glucose and G6P i.e. hexokinase, glucokinase
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Figure 3 Levels of phospholipids, free- and esterified fatty acids
in liver and brain of normal 'Freiburg' mice (n=8-12) after
treatment with 1 gkg-1 Ro-03-8799 i.p. Mean+s.e.
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Figure 4 Activities of liver glucokinase and brain hexokinase of
normal 'Freiburg' mice (n=8-10) after treatment with 1 gkg -
Ro-93-8799 i.p. Mean+s.e.
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and glucose-6-phosphatase (G6P'ase) as well as the ATP
levels were made, to see whether these could offer an
explanation for the divergency in the levels of these glyco-
lytic metabolites in both brain and liver. As shown in Figure
4, neither the hexokinase nor the glucokinase activity was
found to be inhibited in the brain or liver, nor were the
levels of ATP, a limiting factor for this reaction, decreased
(Figure 5). However, the hepatic G6P'ase activity was
enhanced -2-fold by the sensitizer after 1 h, whereas the
activity in the brain was slightly inhibited (Figure 6).
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Figure 5 Levels of ATP in liver and brain of normal 'Freiburg'
mice (n=8-10) after treatment with 1 gkg-1 Ro-03-8799 i.p.
Mean+s.e. P determined by Student's t-test, with respect to
control group.
Metabolic changes in tumour-bearing mice The presence of
adenocarcinoma in C57 mice did not affect the metabolite
levels in either the liver or brain to any great extent. Thus,
the control levels shown in Table II are comparable to those
of normal C57 animals. Only the early changes in metabolite
levels occurring in the tumour, brain and liver within 2h of
administering Ro-03-8799 were studied. Overall the pattern
of changes seen in brain and liver metabolite levels in the
tumour-bearing animals closely resembled that seen in
normal Freiburg animals. In the tumour nearly all
metabolite levels, except for pyruvate, were found to be
significantly enhanced over this period, as a result of which
the redox couples were directed towards the reduced state.
The majority of the metabolic alterations seen in the tumour
are thus in contrast to those in the liver and brain except for
the ketone bodies and brain glucose.
Effects on body temperature
Ro-03-8799 caused a rapid decrease in body temperature
measured in the rectum of normal and tumour-bearing mice
within 15min of application, the lowest temperature
(-32°C) being observed after 1 h (Eigure 7). Thereafter, it
increased steadily and was within normal limits after 3 to 6h.
Discussion
The pharmacokinetic studies reported here show that the
brain/plasma ratio of Ro-03-8799 given i.p. to mice is greater
than unity over an extended period ( -3 h), and this effect
may feature prominently as one of the causes of the central
neuropathy reported to date in patients (Roberts et al.,
1986). Similarly, the enhanced concentration of sensitizer in
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Table II Metabolite levels in brain, liver and tumour of C57 Bl mice at 0, 1 and 2h after i.p. administration of 1 gkg-1 of Ro-03-8799
(nmolg 1 tissue)
Time
(h) P L L/P AcAc fl-HoBu 13-HoBulAcAc FDP DAP G3P G3P/DAP Glucose G6P
Brain 0 93 5,349 58 64 78 1.2 43 44 355 8.1 353 172
+8 +649 +5 +11 +3 +4 +37 +30 +36
1 109b 6,329b 58 77b 87 1.1 29b 58b 256b 4.4 564b 101b
+12 +570 +12 +15 +3 +3 +16 +135 +15
2 91 5,646 62 1ogb 157b 1.4 44 60b 371 6.2 742b I lob
+11 +416 +29 +19 +2 +4 +27 +146 +17
Liver 0 182 3,315 18 89 294 3.3 23 51 619 12.1 10,509 389
+11 +319 +9 +31 +6 +3 +53 +1,124 +51
1 195b 2,169b 1 104b 679b 6.5 15b 74b 182b 2.5 7,366b 345
+12 +173 +20 +126 +2 +10 +18 +1,189 +67
2 167b 1,421b 9 92 558b 6.1 14b 50 398b 8.0 12,188b 384
+12 +156 +9 +26 +2 +4 +45 +1,649 +83
Tumour 0 170 2,800 17 65 130 2.0 25 23 86 3.7 940 245
+15 +200 +16 +8 +3 +3 +9 +120 +29
1 147b 4,920b 34 61 570" 9.3 33 21 110b 5.2 2,770b 333"
+9 +360 +12 +81 +3 +2 +9 +540 +15
2 123" 5,810 47 162b 358b 2.2 28 30" 138" 4.6 1,980b 315b
+21 +390 +15 +46 +4 +2 +16 +300 +18
aP<0.05: Student's t-test; bP<0.01.
Number of animals, n = 12. Data are given as mean +s.d.
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Figure 7 Body temperature in normal 'Freiburg' and tumour-
bearing C57 BI mice after treatment with gkg - Ro-03-8799
i.p.
Figure 6 Glucose-6-phosphatase in liver and brain of normal
'Freiburg' mice (n=8-10) after treatment with lgkg-1 Ro-03-
8799 i.p. Mean + s.e. P determined by Student's t-test, with
respect to control group.
tumour relative to that in the plasma seen between 30 and
60min is in agreement with previous observations (Hill et al.,
1983).
From the results, we have shown that treatment of mice
with single doses of the sensitizer Ro-03-8799 can produce
marked early changes in glucose and lipid metabolism in
normal and tumour tissues in vivo, in much the same way
as demonstrated previously for MISO and SR-2508
(Tamulevicius et al., 1984a). It appears that the oppositely
directed effects on the levels of several glycolytic inter-
mediates seen in the liver, brain and tumour cannot be
explained merely as being due to the resulting hypothermic
condition and consequently a general decrease in the
metabolic rate alone, since doses of 5 mM SR-2508 and
10mM DEMISO have shown similar changes in metabolic
profiles without significantly lowering the body temperature
(Tamulevicius et al., 1984a, and unpublished data). As a
result, the contrasting effects of Ro-03-8799 on liver, brain
and tumour metabolism affect the intracellular compart-
mental NAD+/NADH linked redox couples (L/P, G3P/DAP,
fl-HOBu/AcAc) differently and which, particularly in the
case of the tumour, may lead to an increase in the hypoxic
cell fraction as well as possibly affecting the tissue pH.
Although the hepatic lipid levels are increased, the large
amounts of ketone bodies, particularly f,-HOBu, produced
by the liver are apparently not derived from f-oxidation of
fatty acids but appear to stem from an enhanced oxidation
of glucose to acetyl-CoA during the first few hours and
could also account for the low hepatic lactate levels observed.
This is further underlined by the finding that the sensitizer
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leads to a rapid decrease in the glycogen content in the
liver with an ensuing mobilisation of glucose into the blood,
thus substantiating the key role of glucose-6-phosphatase in
this process. Although the hepatic glucose levels are main-
tained relatively constant, enhanced glucose production and
glycogen degradation could account for the rise in tumour
glucose levels and, as a result of increased anaerobic glyco-
lysis in the tumour, correspondingly lead to an accumulation
of lactate.
Similarly, the early increase in brain glucose levels would
also appear to be of hepatic origin and although glycolysis
apparently proceeds normally, we are unable at present to
explain the early disappearance of G6P levels in the brain,
despite a demonstrable hexokinase activity and sufficient
levels of ATP. However, alterations to transport mechanisms
and glucose utilisation in the brain could also contribute to
the observed effects. Even though the glucose supply to the
brain is in excess of energy demands there is, however, no
indication of Ro-03-8799 greatly affecting the glycolytic
sequence at the phosphofructokinase stage as seen from the
levels of FDP in brain, except perhaps after 1 h, where it was
found to be significantly lowered. Since the ketone bodies
produced by the liver cannot be utilized by this organ
(McGarry & Foster, 1980), the corresponding increases in
both brain and tumour levels are apparently hepatically
derived, because of the non-ketogenic nature of these tissues.
Because the sensitizer markedly affects both phospholipid
and fatty acid metabolism in both brain and liver, alterations
to these pathways may be closely involved in the develop-
ment of both central and peripheral neurotoxicity. The
recent documentation of novel xenobiotic-lipid conjugation
reactions may be of interest in this respect (Caldwell, 1985;
Hutson et al., 1985). From the work of Raleigh et al. (1985),
showing that the hydroxyl group in the side-chain of MISO
can be acetylated chemically, it is conceivable that MISO
may undergo esterification with endogenous fatty acids; one
consequence could be the establishment of tissue residues of
xenobiotic sensitizer in lipid-rich tissues and alterations of
membrane functions.
Although the neurotoxicity of MISO in rats has been
shown to closely resemble that seen in animals fed a
thiamine-deficient diet (Griffin et al., 1979), the role of this
vitamin in preventing or alleviating neuropathy still remains
to be clearly resolved. This also applies to the use of various
forms of vitamin B6 (pyridoxine, pyridoxal, pyridoxal phos-
phate) in attempts to overcome neurotoxicity, particularly in
view of the inconsistent clinical and experimental data
reported by Coleman et al. (1984).
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